Atazanavir
As of the edition of 20 October 2026, Atazanavir is a small molecule: marketed, first approved in 2003 (US); US protection ends in 2029.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2004
- Kind
- Small molecule
- Brand name
- Reyataz
- First approved
- 20 June 2003 (US)
- Approvals on record
- 8 in 2 regions
- Holder of the most recent approval
- Bristol Myers Squibb
- Withdrawn from market
- 23 February 2026 (in some regions)
- Registered trials
- 120, 17 stopped early
- Disease areas
- Infections; Immune system; Urinary and reproductive; Nutrition and metabolism; Skin and connective tissue; Digestive system
US protection
US protection ends in 2029.
The last listed US drug-substance patent ends in 2029. The application that gives this date is held by Bristol Myers Squibb.
This is the US only, and it is not the date generics or biosimilars can enter.
The exact date and the listings behind it
In the product1 listing counts towards this date. The exact date and each listing are in the product.
See the exact date and the 1 listing behind itRequest access. Nothing is shown until you do.
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 19 | 15 | 0 | 2 |
| Phase 1 | 23 | 21 | 0 | 1 |
| Phase 2 | 20 | 15 | 0 | 5 |
| Phase 3 | 28 | 22 | 1 | 5 |
| Phase 4 | 30 | 23 | 1 | 4 |
| All trials | 120 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Bristol Myers Squibb | Originator and Lead sponsor of trials | 1999 to now |